This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma

This study has been withdrawn prior to enrollment.
(This study was for National Science Council project. The study was not funded, so the study was withdrawn.)
Information provided by:
National Taiwan University Hospital Identifier:
First received: September 12, 2005
Last updated: September 25, 2008
Last verified: November 2004

Primary Objective: To study if lycopene can improve the biomarker status of urothelial cells in patients with uremia-associated urothelial carcinoma.

Secondary Objective: To evaluate the general safety and tolerability of oral lycopene 30 mg per day for 12 weeks in uremic patients.

Condition Intervention Phase
Carcinoma, Transitional Cell Drug: Lycopene Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • changes of intermediate biomarker status after lycopene supplementation

Secondary Outcome Measures:
  • safety and tolerability

Estimated Enrollment: 80
Study Start Date: January 2006
Detailed Description:
This is a renal function-stratified phase II chemoprevention trial. After 8 weeks of a run-in and washout period, participants will take lycopene, 30 mg per day for 12 weeks. The expression of intermediate biomarkers will be determined upon study entry after 8 weeks of run-in/washout, and after 6 and 12 weeks of lycopene supplementation. It takes at least 20 weeks to complete the course.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients have pathologically-proven urothelial carcinoma (UC) with a clinical stage <= T3N0M0
  • Patients have no visible or identifiable residual UC after treatment with a life expectancy of > 6 months
  • Patients have remaining urothelium at risk of recurrence (transplanted renal unit excluded)
  • No other active malignancy. Patients who have other primary malignancies should be treated successfully prior to the study entry and should be in a cure or remission state for at least one year.
  • Patients are able to take lycopene capsules orally.
  • Patients who sign and give informed consents and are willing to conform to the scheduled sampling of the blood, urine and/or tissue

Exclusion Criteria:

  • Patients who have clinical stage > T3N0M0 or metastatic disease
  • Positive urine cytology. Patients who have positive cytology should be subjected to a serial diagnostic workup which may include renal echo, cystoscopy and ureterorenoscopy, and image studies (intravenous urography, computed tomography, magnetic resonance urography, retrograde or antegrade pyelography). If no recurrent or residual tumors are found, patients are still eligible for the study.
  • Patients who have ever received systemic chemotherapy within 12 months
  • Patients who have gastrointestinal malabsorption regardless of the etiology
  • Have known allergic reaction to tomato or lycopene
  • Patients who are participating or will participate in other clinical trials
  • Patients who have active urinary tract infection can not be accrued until infection is effectively controlled
  • Patient's age is less than 18 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00172367

National Taiwan University Hospital
Taipei, Taiwan
Sponsors and Collaborators
National Taiwan University Hospital
Principal Investigator: Yeong-Shiau Pu, MD, PhD National Taiwan University Hospital
  More Information Identifier: NCT00172367     History of Changes
Other Study ID Numbers: 930906
Study First Received: September 12, 2005
Last Updated: September 25, 2008

Keywords provided by National Taiwan University Hospital:
Urothelial carcinoma

Additional relevant MeSH terms:
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Radiation-Protective Agents
Anticarcinogenic Agents
Antineoplastic Agents processed this record on September 21, 2017